ArticlePPAR research2008
PPARgamma and Apoptosis in Cancer.
Article in PPAR research, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 57 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
57 citing papers in PubMed, 116 citations in OpenAlex.
- Current State of Knowledge of the Anticancer Properties of Polyphenolic Compounds from Garlic (Molecules (Basel, Switzerland) · 2026Review
- Computational Analysis andCurrent medicinal chemistry · 2026Article
- USP28-Based Deubiquitinase-Targeting Chimeras for Cancer Treatment.Journal of the American Chemical Society · 2025Article
- PPAR-γ in Melanoma and Immune Cells: Insights into Disease Pathogenesis and Therapeutic Implications.Cells · 2025Review
- PPAR-γ agonist pioglitazone and the risks of malignancy among type2 diabetes mellitus patients.Acta diabetologica · 2025Article
- Expression of Peroxisome Proliferator-Activated Receptor γ in Human Colorectal Carcinoma and Its Correlation with Clinicopathological Characteristics.Indian journal of surgical oncology · 2025Article
- Beta-Caryophyllene Augments Radiotherapy Efficacy in GBM by Modulating Cell Apoptosis and DNA Damage Repair via PPARγ and NF-κB Pathways.Phytotherapy research : PTR · 2025Article
- Comparison of the Cytotoxic Mechanisms of Different Garlic (International journal of molecular sciences · 2025Article
- Chiglitazar diminishes the warburg effect through PPARγ/mTOR/PKM2 and increases the sensitivity of imatinib in chronic myeloid leukemia.Experimental hematology & oncology · 2024Article
- Anti-Cancer and Anti-Proliferative Potential of Cannabidiol: A Cellular and Molecular Perspective.International journal of molecular sciences · 2024Review
- Repurposed Drugs Celecoxib and Fmoc-L-Leucine Alone and in Combination as Temozolomide-Resistant Antiglioma Agents-Comparative Studies on Normal and Immortalized Cell Lines, and onInternational journal of molecular sciences · 2024Article
- Induction ofJournal of clinical biochemistry and nutrition · 2023Article
- Altered expression, but small contribution, of the histone demethylase KDM6A in obstructive uropathy in mice.Disease models & mechanisms · 2023Article
- Combined inhibition of histone deacetylase and cytidine deaminase improves epigenetic potency of decitabine in colorectal adenocarcinomas.Clinical epigenetics · 2023Article
- A Bibliometric and In Silico-Based Analysis of Anti-Lung Cancer Compounds from Sea Cucumber.Marine drugs · 2023Review
- Galectin-9 in cancer therapy: from immune checkpoint ligand to promising therapeutic target.Frontiers in cell and developmental biology · 2023Review
- Anoikis in phenotypic reprogramming of the prostate tumor microenvironment.Frontiers in endocrinology · 2023Review
- Elastin-Derived Peptides in the Central Nervous System: Friend or Foe.Cellular and molecular neurobiology · 2022Review
- Soluble TGFBI aggravates the malignancy of cholangiocarcinoma through activation of the ITGB1 dependent PPARγ signalling pathway.Cellular oncology (Dordrecht, Netherlands) · 2022Article
- Alteration of PPAR-GAMMA (PPARG; PPARγ) and PTEN gene expression in acute myeloid leukemia patients and the promising anticancer effects of PPARγ stimulation using pioglitazone on AML cells.Molecular genetics & genomic medicine · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
Peroxisome proliferator-activated receptors (PPARs) are ligand binding transcription factors which function in many physiological roles including lipid metabolism, cell growth, differentiation, and apoptosis. PPARs and their ligands have been shown to play a role in cancer. In particular, PPARgamma ligands including endogenous prostaglandins and the synthetic thiazolidinediones (TZDs) can induce apoptosis of cancer cells with antitumor activity. Thus, PPARgamma ligands have a potential in both chemoprevention and therapy of several types of cancer either as single agents or in combination with other antitumor agents. Accordingly, the involvement of PPARgamma and its ligands in regulation of apoptosis of cancer cells have been extensively studied. Depending on cell types or ligands, induction of apoptosis in cancer cells by PPARgamma ligands can be either PPARgamma-dependent or -independent. Through increasing our understanding of the mechanisms of PPARgamma ligand-induced apoptosis, we can develop better strategies which may include combining other antitumor agents for PPARgamma-targeted cancer chemoprevention and therapy. This review will highlight recent research advances on PPARgamma and apoptosis in cancer.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.